Medicare Panel Debates Coverage for Genetic Testing

During the formal voting, panel members generally agreed that rigorous evidence on survival outcomes would be “sufficient to infer whether or not screening genetic testing is effective for the prevention or early detection of illness or disability.” In terms of the most desirable measures of cost-effectiveness of genetic screening tests, they ranked gains in quality-adjusted life years higher than decreases in incidence of illness or net changes in lifetime illness costs.